Clinical Trial

Mesothelin and Claudin 18.2 Dual-Target CAR-T Therapy in Advanced Pancreatic Cancer

Name: Mesothelin and Claudin 18.2 Dual-Target CAR-T Therapy in Advanced Pancreatic Cancer — clinical trial record (NCT07066995)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: BAH2573-102

Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

Autologous T-cells engineered to express CARs targeting Mesothelin and Claudin18.2, for Unresectable locally advanced or metastatic pancreatic adenocarcinoma (Pancreatic Ductal Adenocarcinoma, PDAC), administered as two separate sequential infusions following lymphodepleting chemotherapy

Trial Details

NCT Number	NCT07066995
Lead Sponsor	Essen Biotech
Conditions	Pancreatic Cancer, Pancreatic Carcinoma, Pancreatic Cancer Non-resectable, Pancreatic Cancer Stage IV
Enrollment	60 participants
Start Date	2025-04-29
Primary Completion	2027-12-10 (estimated)
Study Completion	2028-12-28 (estimated)
Updated on ClinicalTrials.gov	2025-07-15